It is now generally accepted that noradrenaline is the neurohormone of the sympathetic nerves (1-4) and is released as such at the nerve endings. However, it is not understood how the body metabolizes noradrenaline. This paper describes a method for separating and identifying the various metabolic products of noradrenaline in the human and discusses the import of this procedure as a tool for studying those clinical entities which represent an aberration in the physiology of the sympathetic nervous system.As early as 1895 Cybulski (5) showed that extracts of the adrenal medulla, when injected intravenously, increased the pressor activity of the urine. Later Holtz, Credner, Kroneberg and Shiimann (6, 7) and von Euler and Hellner (8) demonstrated that this pressor activity was due to adrenaline, noradrenaline, and, to a far lesser extent, hydroxytyramine. Subsequently, von Euler, Luft and Sundin (9) showed that by infusing adrenaline, 0.4 to 1.7 per cent of the infused adrenaline appeared in the urine, and, in similar experiments performed with noradrenaline (10), 1.5 to 3.3 per cent of the infused noradrenaline was excreted in the urine. This therefore means that over 95 per cent of the adrenaline and noradrenaline is metabolized following release; consequently, the metabolic products which appear in the urine must be in a relatively biologically inactive form.The first of these relatively inactive metabolic products was demonstrated in 1940 by Richter (11). He showed that by ingesting large quantities of adrenaline, a conjugate of adrenaline could be isolated from the urine. He concluded that this conjugate was a sulfate. Beyer and Shapiro (12) performed somewhat similar experiments but concluded that the conjugate was a glucu- ronide. Dodgson, Garton and Williams in 1947 (13) fed rabbits d-adrenaline and isolated from the urine of these rabbits a conjugate of adrenaline. Clark and Drell (14), repeating this work, showed that rabbits metabolized dl-and 1-adrenaline in a similar manner and that the conjugate was a glucuronide.Then in 1952 and 1953 Schayer, Smiley, Kaplan and Kennedy (15-17) published their papers on the metabolism of adrenaline. They not only showed something about the cleavage of adrenaline but pointed out that there were at least five or six urinary catabolites of adrenaline. In 1957 Armstrong, McMillan and Shaw (18,19) identified 3-methoxy-4-hydroxymandelic acid as a major urinary metabolite of adrenaline in the human.Subsequently, Axelrod and associates (20,21) isolated metadrenaline (3-0-methyladrenaline) and normetadrenaline (3 -0-methylnoradrenaline) from rat urine and metadrenaline from human urine. Also in 1957 von Euler (22) demonstrated 3,4-dihydroxymandelic acid in human urine, and in 1958 LaBrosse, Axelrod and Sjoerdsma (23) isolated normetadrenaline from the urine of pheochromocytoma patients. Goodall, Rosen and Kirshner (24,25) infused normal male subjects with labeled dl-adrenaline-2-C" and separated and identified a number of the urinary catabolites of adrenaline. Hitherto, w...